
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune SA is strategically positioned to capitalize on its proprietary technologies aimed at neurodegenerative diseases, particularly with its promising pipeline which includes advanced candidates such as ACI-7104.056, a PD active immunotherapy that has demonstrated a significant 20-fold increase in antibodies targeting pathogenic variants of aSyn. Additionally, the potential positive outcomes from the NLRP3 program and the upcoming EVOKE trial could enhance investor interest, especially as the treatment landscape increasingly favors safer, easily administered agents that effectively identify patients and maximize treatment efficacy.
Bears say
AC Immune SA reported a net operating loss of CHF16.2 million for the quarter, reflecting ongoing financial challenges as a clinical-stage biopharmaceutical company. The firm is subject to significant risks typical of the biotechnology industry, including the possibility of adverse clinical trial outcomes, regulatory hurdles, and heightened complexity in commercial markets that are sensitive to pricing. These factors contribute to a negative outlook for the company as it navigates the uncertain landscape of developing therapeutics for neurodegenerative diseases.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares